New drug combo offered to GIST patients with no other options
NCT ID NCT06948955
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides bezuclastinib, an investigational drug, combined with sunitinib for adults with advanced gastrointestinal stromal tumors (GIST) who cannot tolerate or have progressed on imatinib. The goal is to offer a potential treatment when no satisfactory alternatives exist. Participants must meet specific health criteria and commit to the program's assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bezuclastinib and sunitinib
What this could lead to
If this combination works, it could provide a new treatment option for people with advanced GIST who have run out of standard therapies.
What could go wrong
This is an expanded access program, not a formal trial, so data on effectiveness and safety is limited. The combination may not work for everyone and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS, GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
AVAILABLECleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
-
Dana Farber Cancer Institute (DFCI)
AVAILABLEBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Huntsman Cancer Institute, University of Utah
AVAILABLESalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University
AVAILABLEBaltimore, Maryland, 21287, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
AVAILABLEHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
Mayo Clinic
AVAILABLEJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
AVAILABLERochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Hospital
AVAILABLEPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
AVAILABLENew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Memorial Hospital
AVAILABLEChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Orlando Health
AVAILABLEOrlando, Florida, 32806, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roswell Park Cancer Institute
AVAILABLEBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenandoah Oncology
AVAILABLEWinchester, Virginia, 22601, United States
-
Shenandoah Oncology
AVAILABLEWinchester, Virginia, 22601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Smillow Cancer Hospital - Yale New Haven Health
AVAILABLENew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
-
Taylor Cancer Research Center
AVAILABLEMaumee, Ohio, 43537, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
AVAILABLEColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
The University of Chicago Medical Center
AVAILABLEChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University
AVAILABLEPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA Department of Medicine- Hematology/Oncology
AVAILABLELos Angeles, California, 90095, United States
Contact Email: •••••@•••••
-
UPMC Hillman Cancer Center
AVAILABLEPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC/Norris Comprehensive Cancer Center
AVAILABLELos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado
AVAILABLEAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••